The patent was granted on 2 April 2013 under number US 8,409,818 B2. The grant of this US patent widens the protection from territories where patents have already been granted in South Africa and the member states of the African Intellectual Property Organisation, and with patents pending in many other territories.

Commenting on the patent grant, Andrew Shepherd, CEO of Omega said: "We are delighted to learn of this US Patent award, extending the patent protection which already exists for our novel CD4 point-of-care test, and which is testimony to the years of hard work done by our colleagues at the Burnet Institute in partnership with others.”